Over 115 000 people are waiting for life-saving organ transplants, of whom a small fraction will receive transplants and many others will die while waiting. Existing efforts to expand the number of available organs, including increasing the number of registered donors and procuring organs in uncontrolled environments, are crucial but unlikely to address the shortage in the near future and will not improve donor/recipient compatibility or organ quality. If successful, organ bioengineering can solve the shortage and improve functional outcomes. Studying manufactured organs in animal models has produced valuable data, but is not sufficient to understand viability in humans. Before risking manufactured organ experimentation in living humans, study of bioengineered organs in recently deceased humans would facilitate evaluation of the function of engineered tissues and the complex interactions between the host and the transplanted tissue. Although such studies do not pose risk to human subjects, they pose unique ethical challenges concerning the previous wishes of the deceased, rights of surviving family members, effective operation and fair distribution of medical services, and public transparency. This article investigates the ethical, legal and social considerations in performing engineered organ research on the recently deceased.
- research ethics
- allocation of organs/tissues
- dead donor rule
- donation/procurement of organs/tissues
- allocation of health care resources
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Twitter @parent_brendan, @arthurcaplan
Collaborators NYU Medical Ethics Working Group: Luis Angel, NYU Langone Health; Scott Briggs, Touro College of Medicine; James Childress, University of Virginia; Nancy Dubler, NYU Langone Division of Medical Ethics; Moshe M Cohn, NYU Langone Health; Jared Eckman, NYU Langone Division of Medical Ethics; Sandy Feng, UCSF; Sander Florman, Mt Sinai; Kyle Ferguson, NYU Langone Division of Medical Ethics; Susan Gunderson, LifeSource; Megan Kitts, NYU Langone Division of Medical Ethics; Olivia Scheyer, NYU Langone Division of Medical Ethics; Tamar Schiff, NYU Langone Health; Laura Siminoff, Temple University; Brigitte Sullivan, NYU Langone Health; Angela Turi, NYU Langone Division of Medical Ethics; Stephen Wall, NYU Langone Health.
Contributors Each author was responsible for drafting a different primary content section. BG and SL were responsible for editing all sections down to meet word length requirements. BP is responsible for overall content as guarantor.
Funding This study was supported by United Therapeutics Corporation.
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; internally peer reviewed.
Read the full text or download the PDF:
Other content recommended for you
- Organ donation in the surgical ICU: an American Association for the Surgery of Trauma Critical Care Committee clinical consensus document
- Improving relatives’ consent to organ donation
- The dead donor rule: effect on the virtuous practice of medicine
- Is informed consent required for the diagnosis of brain death regardless of consent for organ donation?
- Organ donation after medical assistance in dying or cessation of life-sustaining treatment requested by conscious patients: the Canadian context
- Canada-DONATE study protocol: a prospective national observational study of the medical management of deceased organ donors
- Ethics of organ procurement from the unrepresented patient population
- The potential for neonatal organ donation in a children's hospital
- Bereaved ICU parental end-of-life care goals: including organ donation regardless of eligibility
- Quality improvement tools to manage deceased organ donation processes: a scoping review